The utility of procalcitonin as a biomarker of hospital-acquired infection in severe COVID-19
Main Article Content
Abstract
Background. Hospital-acquired infection (HAI) in patients with COVID-19 admitted to the intensive care unit (ICU) is associated with increased mortality. The ‘cytokine storm’ associated with COVID-19 leads to extreme elevation of inflammatory biomarkers, including C-reactive protein (CRP). Procalcitonin (PCT) has been shown to be more discriminative than CRP in distinguishing HAI from other inflammatory processes.
Objectives. To investigate the utility of PCT in detecting HAI in patients with severe COVID-19.
Methods. Clinical and laboratory data from all patients admitted to a dedicated ICU with confirmed severe COVID-19 from 1 April 2020 to 31 August 2020 were prospectively captured. HAI was confirmed by serial PCT and CRP measurements, as well as microbiological data (positive microbiological cultures in clinical context). Data from patients who were on antibiotics on ICU admission, had a positive culture for a presumed pathogen during the first 48 hours of ICU admission, or already had suspected or proven HAI on admission were excluded. Optimal cut-offs with the highest sensitivity and specificity were determined. The discriminative power of PCT was assessed for each outcome, using receiver operating characteristic (ROC) analysis describing the area under the curve. Similarly, negative predictive values (NPVs) and positive predictive values (PPVs) were determined. The sensitivity and specificity for different PCT cut-off levels were calculated.
Results. Of 92 patients, 35 had confirmed HAI, which was significantly associated with mechanical ventilation (p<0.001) and mortality (p<0.001). ROC analysis demonstrated that a threshold PCT level of 0.22 μg/L resulted in 97% sensitivity and 40% specificity for predicting HAI. Similarly, sensitivity and specificity for CRP were 91.4% and 38.6%, respectively, when the CRP level was 133 mg/L. In patients with a PCT level <0.25 μg/L, the NPV was 92%, whereas for PCT levels >1.00 μg/L, the PPV was >50%. For PCT levels >40 μg/L, the PPV was 100%.
Conclusion. During HAI, PCT levels >1.00 μg/L had a moderate PPV of 52%, whereas levels <0.26 μg/L ruled out HAI with an NPV of 92%. With increased PCT values, the PPV rose to 100%, making it a better biomarker than CRP.
Downloads
Article Details

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
1. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: A systematic review and meta-analysis. J Infect 2020;81(2):266-275. https://doi. org/10.1016/j.jinf.2020.05.046
2. Moolla MS, Reddy K, Fwemba I, et al. Bacterial infections, antibiotic use and COVID-19: Lessons from the intensive care unit. S Afr Med J 2021;111(6):575- 581. https://doi.org/10.7196/SAMJ.2021.v111i6.15590
3. Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol 2020;127:104370. https:// doi.org/10.1016/j.jcv.2020.104370
4. Cleland DA, Eranki AP. Procalcitonin. Updated 23 April 2023. In: StatPearls (Internet). Treasure Island, Fla.: StatPearls Publishing, January 2024. https://www. ncbi.nlm.nih.gov/books/NBK539794/ (accessed 28 July 2021).
5. Hoeboer SH, van der Geest PJ, Nieboer D, Groeneveld ABJ. The diagnostic accuracy of procalcitonin for bacteraemia: A systematic review and meta- analysis. Clin Microbiol Infect 2015;21(5):474-481. https://doi.org/10.1016/j. cmi.2014.12.026
6. Van Berkel M, Kox M, Frenzel T, Schouten J; RCI-COVID-19 study group. Biomarkers for antimicrobial stewardship: A reappraisal in COVID-19 times? Crit Care 2020;24(1):600. https://doi.org/10.1186/s13054-020-03291-w
7. Pink I, Raupach D, Fuge J, et al. C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19. Infection 2021;49(5):935-943. https:// doi.org/10.1007/s15010-021-01615-8
8. Roy A, Powers HR, Craver EC, et al. Antibiotic stewardship: Early discontinuation of antibiotics based on procalcitonin level in COVID-19 pneumonia. J Clin Pharm Ther 2022;47(2):243-247. https://doi.org/10.1111/jcpt.13554
9. Heer RS, Mandal AKJ, Kho J, et al. Elevated procalcitonin concentrations in severe Covid-19 may not reflect bacterial co-infection. Ann Clin Biochem 2021;58(5):520-527. https://doi.org/10.1177/00045632211022380
10. Garrido P, Cueto P, Rovira C, et al. Clinical value of procalcitonin in critically ill patients infected by SARS-CoV-2. Am J Emerg Med 2020;46:525-531. https://doi. org/10.1016/j.ajem.2020.11.011
11. Li Y, Guo J, Yang H, Li H, Shen Y, Zhang D. Comparison of culture-negative and culture-positive sepsis or septic shock: A systematic review and meta-analysis. Crit Care 2021;25(1):167. https://doi.org/10.1186/s13054-021-03592-8